Parcion Private Wealth LLC Buys 554 Shares of Johnson & Johnson (NYSE:JNJ)

Parcion Private Wealth LLC boosted its position in Johnson & Johnson (NYSE:JNJ) by 7.9% during the third quarter, Holdings Channel reports. The fund owned 7,584 shares of the company’s stock after acquiring an additional 554 shares during the period. Parcion Private Wealth LLC’s holdings in Johnson & Johnson were worth $1,229,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in JNJ. Asio Capital LLC lifted its holdings in shares of Johnson & Johnson by 2.9% in the 1st quarter. Asio Capital LLC now owns 31,774 shares of the company’s stock worth $5,026,000 after acquiring an additional 903 shares during the last quarter. Kathmere Capital Management LLC lifted its stake in Johnson & Johnson by 21.5% in the first quarter. Kathmere Capital Management LLC now owns 15,317 shares of the company’s stock worth $2,423,000 after purchasing an additional 2,711 shares during the last quarter. Webster Bank N. A. boosted its position in Johnson & Johnson by 0.6% during the first quarter. Webster Bank N. A. now owns 51,953 shares of the company’s stock valued at $8,218,000 after buying an additional 285 shares during the period. S.E.E.D. Planning Group LLC grew its stake in shares of Johnson & Johnson by 16.8% during the first quarter. S.E.E.D. Planning Group LLC now owns 33,344 shares of the company’s stock valued at $5,275,000 after buying an additional 4,797 shares during the last quarter. Finally, Norris Perne & French LLP MI increased its holdings in shares of Johnson & Johnson by 4.1% in the first quarter. Norris Perne & French LLP MI now owns 107,328 shares of the company’s stock worth $16,978,000 after buying an additional 4,203 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.16% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on JNJ shares. Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. TD Securities cut their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Morgan Stanley upped their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Finally, Sanford C. Bernstein upped their price objective on shares of Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Six investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $175.93.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $160.88 on Monday. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The stock has a market cap of $387.19 billion, a price-to-earnings ratio of 10.03, a PEG ratio of 2.90 and a beta of 0.52. The business’s fifty day moving average is $163.41 and its 200 day moving average is $155.10. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.46%. The company had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. During the same period last year, the business earned $2.66 EPS. Johnson & Johnson’s quarterly revenue was up 5.2% compared to the same quarter last year. Research analysts expect that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.08%. Johnson & Johnson’s payout ratio is currently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.